Related Experiment Video

Updated: Oct 25, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question

Serena Janho Dit Hreich1,2,3, Jonathan Benzaquen1,2,3, Paul Hofman1,2,3,4,5

  • 1Université Côte D'Azur, CNRS, INSERM, IRCAN, 06108, Nice, France.

Purinergic Signalling
|August 4, 2021
PubMed

Insights

The P2RX7 receptor plays a key role in antitumor immunity. Activating the ATP/P2RX7/NLRP3/IL-18 pathway shows promise for enhancing cancer treatments and improving patient outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Solid tumors often resist current treatments, necessitating novel therapeutic strategies.
  • The P2RX7 receptor (P2XR7) is recognized as a crucial regulator of the antitumor immune response.
  • Understanding P2RX7's role in cancer is vital for developing effective therapies.

Purpose of the Study:

  • To review recent findings on cellular mechanisms linking P2RX7 to cancer hallmarks.
  • To explore the therapeutic potential of the ATP/P2RX7/NLRP3/IL-18 pathway in cancer treatment.

Main Methods:

  • Literature review of cellular mechanisms and cancer hallmarks.
  • Analysis of studies investigating the ATP/P2RX7/NLRP3/IL-18 pathway.
  • Synthesis of current research on P2RX7's role in antitumor immunity.

Main Results:

  • P2RX7 activation influences multiple cancer hallmarks.
  • The ATP/P2RX7/NLRP3/IL-18 pathway is implicated in modulating immune responses against tumors.
  • Evidence suggests P2RX7 activation can enhance anti-cancer immunity.

Conclusions:

  • The P2RX7 receptor is a significant target for cancer immunotherapy.
  • Activating the ATP/P2RX7/NLRP3/IL-18 pathway offers a promising strategy to combat cancer progression.
  • Further research into P2RX7 modulation could lead to improved patient care for solid tumors.
Keywords:
Antitumor immunityEctonucleasesImmunotherapiesP2X7Purinergic signalingTumors

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.9K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.1K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
15.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K